Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.07 USD | +2.34% | +2.49% | -12.03% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.03% | 4.67B | |
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+45.32% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Morgan Stanley Trims Price Target on CRISPR Therapeutics to $42 From $43, Keeps Underweight Rating